Skip to content
PeptideTech
Cart

Home / Research library / BAM15 Capsules

Other compounds

BAM15 Capsules: molecular data, studies & sources

BAM15 Capsules is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular record not yet resolved

A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.

MF: not assigned · MW: not assigned · Structure: not assigned

Registered clinical trials

Studies registered on ClinicalTrials.gov that list BAM15 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received BAM15, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

    Preclinical research, reviews & other publications

    Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

    1. Preclinical / laboratory research

      BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils.

      Tsuji N, Tsuji T, Yamashita T et al. · The Journal of clinical investigation · 2023

      PMID 36757801 · DOI: 10.1172/JCI152401

    2. Preclinical / laboratory research

      Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease.

      Zhou M, Li C, Byrne FL et al. · Acta physiologica (Oxford, England) · 2024

      PMID 39152636 · DOI: 10.1111/apha.14217

    3. Review · secondary evidence

      BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases.

      Xiong G, Zhang K, Ma Y et al. · Frontiers in endocrinology · 2023

      PMID 37900126 · DOI: 10.3389/fendo.2023.1252141

    4. Research publication · design requires review

      BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis.

      Zhong S, Shen H, Dai X et al. · Atherosclerosis · 2025

      PMID 40393254 · DOI: 10.1016/j.atherosclerosis.2025.119226

    5. Preclinical / laboratory research

      BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control.

      Axelrod CL, King WT, Davuluri G et al. · EMBO molecular medicine · 2020

      PMID 32519812 · DOI: 10.15252/emmm.202012088

    6. Research publication · design requires review

      BAM15 Relieves Neurodegeneration in Agedand Extends Lifespan.

      Cho I, Song HO, Ji HE et al. · Metabolites · 2022

      PMID 36422268 · DOI: 10.3390/metabo12111129

    7. Preclinical / laboratory research

      The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.

      Gao ZX, Cui ZL, Zhou MR et al. · Biochemical pharmacology · 2022

      PMID 35192847 · DOI: 10.1016/j.bcp.2022.114948

    8. Research publication · design requires review

      Mitochondrial uncoupler BAM15 ameliorates liver lipid metabolism disorders by activating the AMPK pathway.

      Liu Z, Wang W, Wang S et al. · The FEBS journal · 2026

      PMID 41527408 · DOI: 10.1111/febs.70400

    BAM15 Capsules supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

    Reference sources & further reading

      The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

      Search for additional research

      These links run searches; their results have not been individually reviewed and can include unrelated compounds.

      Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

      Related research profiles

      Other compounds

      AICAR

      C9H14N4O5

      258.23 g/mol · PubChem CID 17513

      4 selected publications · 3 human intervention studies · 4 registered trials

      Small molecule · highest stage: Phase 3

      Structure, studies & sources →

      Other compounds

      Enclomiphene

      C26H28ClNO

      406.0 g/mol · PubChem CID 1548953

      5 selected publications · 3 human intervention studies · 22 registered trials

      Small molecule · highest stage: Phase 3

      Structure, studies & sources →